JAGX
Jaguar Animal Health IncNASDAQ
Healthcare • Biotechnology
$0.40-0.69%
Close Nov 6, 2026
- Market cap
- $939.34K
- 1 month
- -91.1%
- 3 months
- -99.8%
- 1 year
- -100.0%
- Dividend
- No dividends on record
- Short interest
- 48.6% of float140.6K shares · settled Oct 15, 2026 · +67.0% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- $27.82M
- Net income
- -$36.65M
- Free cash flow
- -$6.73M
- Book value
- $6.62M
- Total debt
- $16.65M
- P/E
- —
- Price / sales
- 0×
- Price / book
- 0.1×
- FCF yield
- -716.0%
- Net margin
- -131.8%
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About Jaguar Animal Health Inc
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.
Read more
Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
- Website
- jaguar.health
- Headquarters
- San Francisco, CA, United States
- Employees
- 47
- Listed
- May 13, 2015
- Fiscal year ends
- December
Company profile from EODHD, stored Nov 6, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Aug 19, 2026 | $1.2M | -58.9% | 15.8% | -$7.6M | -$12.7M |
| Mar 2026filed May 20, 2026 | $20.3M | +815.6% | 94.3% | $10.2M | $8.6M |
| Dec 2025 | $3.2M | -7.8% | 32.0% | -$20.4M | -$23.1M |
| Sep 2025filed Nov 14, 2025 | $3.1M | -0.8% | 82.7% | -$7.2M | -$9.5M |
| Jun 2025filed Aug 14, 2025 | $3.0M | +9.5% | 82.3% | -$8.0M | -$10.4M |
| Mar 2025filed May 15, 2025 | $2.2M | -5.8% | 76.7% | -$9.4M | -$10.5M |
| Dec 2024filed Mar 31, 2025 | $3.5M | — | 84.1% | -$8.2M | -$9.9M |
| Sep 2024filed Nov 13, 2024 | $3.1M | +10.5% | 82.6% | -$7.3M | -$9.9M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched JAGX. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
140,557 shares short
+56,401 shares (+67%) vs Sep 30, 2026
48.6% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
84,156 shares short
A split falls between these reports; the share-count change is not compared.
24.6% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
326,132 shares short
+84,131 shares (+34.8%) vs Aug 31, 2026
56.6% of the stored float. Published Sep 24, 2026.
Settlement Aug 31, 2026
242,001 shares short
+124,964 shares (+106.8%) vs Aug 14, 2026
Share of float unavailable. Published Sep 10, 2026.
Settlement Aug 14, 2026
117,037 shares short
+29,884 shares (+34.3%) vs Jul 31, 2026
Share of float unavailable. Published Aug 25, 2026.
Settlement Jul 31, 2026
87,153 shares short
+35,466 shares (+68.6%) vs Jul 15, 2026
Share of float unavailable. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind JAGX’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
1 for 15 · reverse split
Effective Sep 17, 2026
Each 15 pre-split shares become 1 post-split share.
Source: EODHD
1 for 35 · reverse split
Effective Apr 30, 2026
Each 35 pre-split shares become 1 post-split share.
Source: EODHD
1 for 25 · reverse split
Effective Mar 24, 2025
Each 25 pre-split shares become 1 post-split share.
Source: EODHD
1 for 60 · reverse split
Effective May 23, 2024
Each 60 pre-split shares become 1 post-split share.
Source: EODHD
1 for 75 · reverse split
Effective Jan 23, 2023
Each 75 pre-split shares become 1 post-split share.
Source: EODHD
1 for 3 · reverse split
Effective Sep 8, 2021
Each 3 pre-split shares become 1 post-split share.
Source: EODHD
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if JAGX is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: LOW
1 smart-money holders: institutions with a high Holder IQ
Q1 2026, filed Jul 8, 2026
Note: 13F filings are reported up to 45 days after quarter-end.Insider context
Sentiment: unknown
No recent insider trades detected.
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 4
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Get the Full Analysis for JAGX
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.
Similar-size companies in Healthcare
VBIO · Valion Bio IncVRAX · Virax Biolabs Group Limited Ordinary SharesARTL · Artelo Biosciences IncNXL · Nexalin Technology Inc.LABT · Lakewood-Amedex Biotherapeutics Inc. Common StockMNDR · Mobile-health Network Solutions Class A Ordinary SharesPOAS · Phaos Technology Holdings (Cayman) LimitedBDRX · Biodexa Pharmaceticals